Oral and Topical Tranexamic Acid for the Treatment of Melasma
Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
Tranexamic acid has been used for treating melasma due to its effect on decreasing the
activity of tyrosinase and melanogenesis. This 3-arm clinical trial will asess the efficacy
and safety of oral and topical tranexamic acid as monotherapy compared with topical
hydroquinone for 12 weeks in adults with melasma. The primary outcome will be the percentage
of reduction at 12-week period of mMASI and melanin index. The incidence of adverse effects
will be reported at weeks 4, 8 and 12.